ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Competing Risks Analysis for Neutrophil to Lymphocyte Ratio as a Predictor of Diabetic Nephropathy Incidence.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diabetic nephropathy (DN) is a serious complication of diabetes mellitus. A high level of neutrophil-lymphocyte ratio (NLR) is an indicator of abnormal immune system activity which may serve as an effective potential inflammatory marker for identifying the risk of DN. This study aimed to investigate the relationship between neutrophil-lymphocyte ratio (NLR) and the incidence of DN in type 2 diabetes mellitus (T2DM) patients. Patients and Methods: DN incidence was defined as the time from baseline diabetes diagnosis to first DN occurrence (KDIGO CKD criteria). NLR's effect and interactions were evaluated using covariate-adjusted competing risks regression (death as competing event). The optimal NLR cut-point for DN prediction was determined by ROC analysis. The Fine and Gray subdistribution hazard model assessed NLR's effect on DN incidence, with subdistribution hazard ratios (sHR) validated via bootstrap sampling. The final sample consisted of the records of 220 individuals (median age 64 years (IQR: 55-72)) with T2DM with complete covariates information which were available for incidence analysis with NLR. Results: Among 220 T2DM patients with complete covariates, 133 (60.45%) developed DN at 6 years, 20 (9.10%) were lost to competing events, and 67 remained DN-free. Median NLR was 2.4 (IQR: 1.8-3.3), positively correlating with urinary albumin-to-creatinine ratio and negatively with the estimated glomerular filtration rate (eGFR) ( Conclusion: NLR shows promise for predicting DN incidence in Chinese patients, especially those >65 years or with good glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.